Concise Prescribing Info
Dosage/Direction for Use
Adult: PO Patients with BMI ≥30 mg/m2 or ≥27 kg/m2 with associated risk factors (e.g. hypertension, diabetes, dyslipidaemia): 120 mg tid with each main meal. Patients with BMI ≥28 kg/m2 irrespective of any risk factors: 60 mg tid. Omit dose if a meal is missed or contains no fat. Discontinue if patient is unable to lose at least 5% of the body weight during the 1st 12 weeks of therapy. All doses given in conjunction with mildly hypocaloric diet.
Should be taken with food. Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.
Cholestasis and chronic malabsorption syndrome. Pregnancy and lactation.
Special Precautions
Patients with diabetes, thyroid disease, epilepsy, anorexia nervosa, bulimia, history of hyperoxaluria or Ca oxalate nephrolithiasis. Renal and hepatic impairment. Monitoring Parameters Monitor BMI, weight, diet (calorie and fat intake), LFT, renal function, serum glucose (in patient with diabetes), thyroid function (in patient with thyroid disease), INR (patient taking warfarin). Rule out other causes of obesity (e.g. hypothyroidism) prior to initiation of therapy.
Adverse Reactions
Significant: Rectal bleeding, decreased prothrombin and increased INR, cholelithiasis, oxalate nephropathy that may lead to renal failure. Gastrointestinal disorders: Oily spotting, flatus with discharge, faecal urgency and incontinence, fatty/oily stool, oily evacuation, flatulence, soft or liquid stools, abdominal pain, increased defaecation, diverticulitis, pancreatitis, rectal discomfort, abdominal distension (patient with type 2 diabetes), tooth and gingival disorder. General disorders and administration site conditions: Fatigue. Immune system disorders: Hypersensitivity reactions (e.g. anaphylaxis, bronchospasm, angioedema, pruritus, rash, urticaria). Infections and infestations: Influenza. Investigations: Increased transaminases and alkaline phosphatase. Metabolism and nutrition disorders: Hypoglycaemia (patient with type 2 diabetes), pedal oedema. Musculoskeletal and connective tissue disorders: Back or leg pain, myalgia. Nervous system disorders: Headache. Psychiatric disorders: Anxiety. Reproductive system and breast disorders: Menstrual irregularity, vaginitis, UTI. Respiratory, thoracic and mediastinal disorders: Upper and lower respiratory infection. Skin and subcutaneous tissue disorders: Bullous eruption.
Potentially Fatal: Severe liver injury with hepatocellular necrosis or acute hepatic failure and hepatitis.
Drug Interactions
Reduces the plasma levels of ciclosporin thereby may decreasing immunosuppressive efficacy. May decrease efficacy of antiretroviral drugs (e.g. atazanavir, ritonavir, tenofovir). May decrease the absorption of fat-soluble vitamins (A, D, E, K), β-carotene, anticoagulants (e.g. warfarin), iodine salts and/or levothyroxine and antiepileptic drugs (e.g. valproate, lamotrigine). May cause hormonal contraceptive failure. May decrease the plasma levels of amiodarone.
CIMS Class
ATC Classification
A08AB01 - orlistat ; Belongs to the class of peripherally acting antiobesity products.
Disclaimer: This information is independently developed by CIMS based on orlistat from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in